Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_3

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Detailed Status

Completed2

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 32 (66.7%)

Trials by Status

completed267%

not_yet_recruiting133%

Recent Activity

0 active trials

Showing 3 of 3

not_yet_recruitingphase_3

Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch

NCT07540416

completedphase_2

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)

NCT04676659

completedphase_3

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

NCT00148460

Clinical Trials (3)

Showing 3 of 3 trials

NCT07540416Phase 3

Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch

Not Yet Recruiting

NCT04676659Phase 2

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)

Completed

NCT00148460Phase 3

Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3